Is determination of angiogenic activity in human tumours clinically useful? Pro

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 609-613

  Ellis, L M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 0032036539     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10040-5     Document Type: Article

References (49)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?-1G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986, 46, 467-473.
2. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Nad Cancer Inst 1990, 82, 4-6.
3. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 1996, 32A, 2485-2493.
4. Srivastava A, Laidler P, Hughes LE, Woodcock J, Shedden EJ. Neovascularization in human cutaneous melanoma: a quantitative morphologic and Doppler ultrasound study. Eur J Cancer Clin Oncol 1986, 22, 1205-1209.
5. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate thickness (.76-4.Omm thick) skin melanoma: a quantitative histologie study. Am J Pathol 1988, 133, 419-423.
6. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N EnglJ Med 1991,324, 1-8.
7. Gasparini G, Folkmam J. Basic and clinical research on angiogenesis. Eur J Cancer 1996, 32A(14), 2379-2540.
8. 2deoxuridine. J Natl Cancer Inst 1970, 45, 773.
9. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 34, 997-1003.
10. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 32A, 2474-2484.
11. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990, 50, 6130-6138.
12. Fidler I, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst 1990, 82, 166-168.
13. Rak J, Filmus J, Kerbel R. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996, 32A, 2438-2450.
14. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996, 32A, 2534-2539.
15. Visscher DW, Smilanetz S, Drozdowicz S, Wykes SM. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 1993, 15, 88-92.
16. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and VEGF expression as prognostic factors in node-negative colon cancer. Arch Surg 1997, 132, 541-546.
17. Toil M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumour angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, 1045-1049.
18. Maeda K, Chung Y, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996,77, 858-863.
19. Pötgens AJG, Altena MC van, Lubsen NH, Ruiter DJ, Waal RMW de. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol 1996, 148, 1203-1217.
20. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor. CancerRes 1995, 55, 5296-5301.
21. Warren R, Yuan H, Math M, Gillett N, Ferrara N. Regulation by vascular endothelial growth factor of human colon tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95, 1789-1797.
22. Fidler IJ, Ellis LM. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
23. Mattern J, Koomägi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995, 6, 1059-1062.
24. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73, 931-934.
25. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin CancerRes 1995, 1, 961-964.
26. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin CancerRes 1996, 2, 1679-1684.
27. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. CancerRes 1995, 55, 3964-3968.
28. Fujimoto K, Ichimori Y, Yamaguchi H, et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 1995, 86, 182-186.
29. Fujimoto K, Ichimori Y, Kakizoe T, et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biaphys Res Commun 1991, 180, 386-392.
30. Duensing S, Grosse J, Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 1995, 15, 2331-2333.
31. Sliutz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G, Kainz C. Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 1995, 94, 277-231.
32. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995, 15, 2675-2677.
33. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995, 76, 2304-2311.
34. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993,85, 241-243.
35. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996,7, 843-848.
36. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996, 2, 821-826.
37. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst 1992,84, 1875-1887.
38. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994, 12, 454-466.
39. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 1994, 29, 109-116.
40. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996, 88, 1764-1769.
41. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992,340, 1120-1124.
42. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Im J Cancer 1993, 55, 371-374.
43. Kitadai Y, Ellis LM, Takahashi Y, et al. Multiparametric in situ mRNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res 1995, 1, 1095-1102.
44. Kitadai Y, Ellis LM, Tucker SL, et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996, 149, 1541-1551.
45. Gasparini G, Barbareschi M, Boacchi P, et al. 67-KDα lamininreceptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 1995,60,604-610.
46. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sei Am 1995, 1, 131-141.
47. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996, 2, 1191-1198.
48. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996, 32A, 2451-2460.
49. Teicher BA, Emi Y, Kakeji Y, Northey D. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer 1996, 32A, 2461-2466.